Drug intelligence / Profile preview

cefepime + dextrose

Development stage
Unknown
Lead developer
B. Braun
Modality
Small Molecules
Administration
Intravenous
01

Overview

Cefepime + dextrose is a combination product consisting of the antibiotic cefepime (as cefepime hydrochloride) and dextrose as a diluent, supplied in a dual-chamber intravenous (IV) container. Cefepime is a fourth-generation, broad-spectrum cephalosporin antibiotic that acts by interfering with bacterial cell wall synthesis, leading to cell lysis and death. The dextrose component serves as an intravenous diluent (5% dextrose in water). This combination is primarily indicated for moderate to severe pneumonia (including cases with bacteremia), empiric therapy for febrile neutropenic patients, uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and, in combination with metronidazole, complicated intra-abdominal infections; all due to susceptible bacterial strains. The product is supplied in a flexible dual-chamber, single-use DUPLEX container for IV use only[1].

Brand names
Cefepime for Injection USP and Dextrose Injection USPDUPLEX
Other names
cefepime in dextrosecefepime hydrochloride and dextrose
02

Targets

PBP2 (Penicillin-binding protein 2)PBP1b (Penicillin-binding protein 1B)

Beyond the preview

Go deeper on cefepime + dextrose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefepime + dextrose.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call